Coherus BioSciences has been somewhat clandestine about its proposed biosimilar to Amgen’s Neulasta Onpro (pegfilgrastim) on-body injector device, but on its newly approved novel autoinjector form, the “first innovation in the pegfilgrastim space in eight years,” the company had been completely tight-lipped.
Coherus Pulls A Rabbit Out Of The Hat With Inventive Pegfilgrastim Form
Firm Guiding For Q2 Launch, On-Body Injector Set To Follow Later In 2023
Coherus’ year-end financial results included a surprise – a newly approved formulation of pegfilgrastim.
More from Products
• By
The elimination of the policy division at the Office of Generic Drugs, tariffs, the Section 232 investigation, and a new executive order to promote lower drug prices seem to both cause and purport to solve the same problem: supply chain disruption.
• By
Sunshine Biopharma is continuing to roll out generic launches in Canada, with its latest product challenging Afinitor and other everolimus rivals in the market.
• By
Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
More from Generics Bulletin
• By
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
• By
Celltrion’s adalimumab biosimilar was crowned as interchangeable by the FDA, at a time when the future of the designation is unknown.
• By
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.